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Abstract
Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study
reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and
mortality of patients with DVT. Methods: PREFER VTE was a prospective, observational study, conducted in 7 European
countries, designed to provide data concerning treatment patterns, resource utilization, mortality, and QoL. First-time or
recurrent patients with DVT were followed at 1, 3, 6, and 12 months. Health-related QoL—as measured by the EuroQoL 5-
Dimension 5-Level instrument ( EQ-5D-5L)—was analyzed using Tobit regression with repeated measures, assessing the impact
of baseline characteristics stratified by cancer activity. Mortality was analyzed using logistic regression. Results: At baseline,
patients with DVT had a 0.14 lower EQ-5D-5L index score (0.72 for total sample) compared to the reference UK population
(0.85). The EQ-5D-5L index score improved from baseline to 12 months in patients with active cancer (from 0.70 to 0.79) and
those without (0.72-0.87); 7.3% died within a year, a 5.2% excess mortality compared to the age- and gender-adfjusted general
population. The 12-month mortality rate of DVT varied between 2.9% in the pooled data from Germany, Switzerland, or Austria
and 15.4% in Italy. Furthermore, the mortality rate differed between patients with active cancer and those without (42.9% vs
4.7%).Conclusions:Deep vein thrombosis is associated with a substantial burden of illness in terms of HrQoL at baseline, which
following treatment normalizes after 12 months and has a significant mortality rate. In addition, active cancer has a significant
impact on mortality and the HrQoL of patients with DVT.
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Introduction
Acute venous thromboembolism (VTE), including deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a com-
mon disorder, with an annual incidence of approximately 1 or 2
cases per 1000 persons.1-3 Patients with VTE have increased
morbidity and mortality related not only to VTE but also to
cancer, surgical procedures, and other medical conditions.4
Moreover, the burden of VTE may well be underestimated.3
In 2005, the UK Health Select Committee estimated that
hospital-acquired VTE alone is responsible for between
25 000 and 32 000 deaths annually in the United Kingdom.5
Given the presence of many comorbidities, the number of
potential preventable deaths are uncertain but likely to be sub-
stantial. The burden of VTE includes impaired quality of life
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(QoL), additional costs of treatment, and potentially indirect
costs due to days lost from work. As such, effective treatment
and prevention is imperative. Current guidelines support the
use of anticoagulants that decrease mortality and recurrence
rates but are also associated with an increased risk of bleeding
that is associated with its own burden. Additionally, traditional
treatment may require frequent international normalized ratio
measurements often by specialized outpatient services.
An epidemiologic modeling study from 2007 offers valu-
able insights in the burden of VTE in Europe.3 This study
estimated an annual number of symptomatic DVT events of
684 000. The total costs of VTE were estimated at €3 billion
per year. To supplement these findings, real-life observational
data are worthwhile. The PREFER VTE registry was partly set
up to offer such data. This study—as described in Agnelli
et al6—was established to assess the real-life acute and mid-
term management of patients with VTE, the use of health-care
resources, and to provide data to estimate the costs for
12 months treatment following a first-time and/or recurrent
VTE diagnosis in hospitals or specialized centers in Europe.
With this registry, data were collected about clinical outcomes,
treatment satisfaction, and health-related quality of life
(HrQoL) as measured by the EuroQoL 5-Dimension 5-Level
instrument (EQ-5D-5L). This manuscript aims to offer
supplementary insights into the burden of illness for patients
with DVT from a European perspective concentrating on
mortality and HrQoL. Within this scope, differences per
country and differences between patients with and without
active cancer are reported and patient characteristics associated
with increased mortality and/or morbidity are identified. A
separate publication is available dealing with health-care
resource use and productivity loss.7
Data and Methods
Setting and Study Population
The PREFER VTE registry was a prospective, observational,
multicenter study with a follow-up of 12 months and 3545
consecutive enrolled patients from 381 centers (311 active cen-
ters, ie, centers that enrolled at least 1 patient) in 7 European
countries (Austria, France, Germany, Italy, Spain, Switzerland,
and the United Kingdom) between January 2013 and July 2014.
Prior to study commencement, the registry protocol was
approved by the responsible ethics committees for the partici-
pating countries and the relevant hospital-based institutional
review boards. All patients enrolled in the registry provided
written informed consent. The outline of the study has been
previously described.6 Briefly, patients were eligible to be
enrolled into the registry if they were at least 18 years, had a
symptomatic, and objectively confirmed first-time or recurrent
acute VTE (the index event) defined as either distal or proximal
DVT or PE or both. Patients were recruited within 2 weeks
of the index event and no exclusion criteria applied. At
baseline, patients were assessed through a face-to-face inter-
view in terms of their demography, disease, previous
clinical events, risk factors, comorbidities, and presented
PE/DVT symptoms, as well as previous treatments. At 1,
3, 6, and 12 months, information regarding the occurrence
of clinical event, treatment, resource utilization, HrQoL, and
treatment satisfaction during each follow-up interval was
measured. The current study concerned patients with DVT,
of which 2056 were recruited.
Data Quality Control
The validity of the data entered into the database was assured
by training investigators on data collection ensuring a uniform
method. Furthermore, a random audit was performed on the
centers included in the registry. During these visits, the monitor
verified informed consent documentation, performed source
data verification against patient’s medical records, and con-
trolled consecutiveness of patient enrolment at site. The data
collection comprised 2 different sources. These sources
included the hospitals or specialized centers at the time of
diagnosis of acute VTE and, as hospital-based investigators
do not always see patients in the following year for routine
clinical care, patients were also asked to participate in
follow-ups by phone, safeguarding the collection of resource
consumption data. Information was collected directly from
patients during standardized phone calls at 1, 3, 6, and
12 months after baseline. The data entered in the database were
checked electronically for completeness and plausibility at the
time of data entry and additional validation was performed on
data sets.
Analyses and Statistics
Descriptive statistics of baseline measurements were provided,
including demographic (age, gender, body mass index [BMI],
marital status, and country), clinical factors (with previous
VTE event, distal vs proximal, and [un]provoked; note 1),
previous clinical event (within 3 years prior to enrollment:
myocardial infarction, coronary heart disease, percutaneous
coronary intervention, atrial fibrillation, transient ischemic
attack, stroke, or bleeding event), risk factors (within past
3 months or ongoing: active cancer, prolonged immobilization,
>5 days in bed, varicose veins, history of major surgery or
trauma), comorbidities (hypertension, congestive heart failure,
vascular disease, dyslipidemia, diabetes, chronic venous
insufficiency, renal disease, liver disease, chronic respiratory
disease, arthritis, lower extremity paralysis, bone fracture/soft-
tissue trauma, alcohol use, smoking history, thrombophilia, and
cardiovascular disease), and the presence of DVT symptoms.
Treatment at baseline and use of heparin, vitamin K antagonist
(VKA), or direct oral anticoagulants (DOACs) are also tabu-
lated. Patients receiving ongoing treatment for cancer are
labeled as “active cancer” patients. Country-specific differ-
ences are analyzed for which Austria, Switzerland, and
Germany are combined into one prespecified region label
(DACH). The DACH countries were grouped as patient popu-
lation, practice patterns and health-care systems were assumed
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to be similar, and the number of sites for Germany, Austria, and
Switzerland were, respectively, 74, 5, and 3. Further details are
described elsewhere.8
Health-related quality of life. The analysis of HrQoL was per-
formed using the EQ-5D-5L.9 The EQ-5D-5L data were col-
lected through face-to-face interview at baseline and by
telephone interview during the follow-up. The EQ-5D has
5 dimensions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Within each dimension, one may
have no problems, slight problems, moderate problems, severe
problems, or extreme problems. Based on the individual
response to the descriptive system (5 dimensions and their
responses), a health state can be defined (eg, 11111 or
21112). For each health state, an index score is assigned, which
represents social preference toward each state. The distribution
of responses of each dimension and EQ-5D-5L index score at
baseline and each follow-up were presented by country and
cancer subgroups. The population reference values of
EQ-5D-5L index scores, based on the UK EQ-5D-5L valuation
study,10 were compared to the DVT population. Subsequently,
the association between baseline characteristics and the EQ-5D
index score was assessed using a Tobit regression model with
repeated measures. The baseline characteristics included age,
gender, BMI, previous clinical events, clinical factors, comor-
bidities, and risk factors. Symptoms at baseline, which were
significantly related to HrQoL, were excluded from the analy-
sis. There is an upper limit of one in the EQ-5D-5L index score,
and up to 5 assessments for any one patient were made over the
1-year follow-up. As a sensitivity analysis, the impact of VTE
recurrence and bleeding events during follow-up and the
impact of treatment on the EQ-5D-5L index score were tested.
Mortality. Following enrolment in the registry, mortality data
were collected at baseline and at each follow-up through a
standardized questionnaire completed by the investigator. The
primary outcomes were 12-month mortality rates by country,
for patients with and without active cancer. The observed DVT
patient mortality rates were compared with the age- and
gender-matched mortality rate from the UK general popula-
tion.11 Separate logistic regression models were used to iden-
tify which individual baseline characteristics and DVT
symptoms were significantly associated with mortality in both
groups after backward stepwise elimination. Additionally,
logistic regression models were run after adding the HrQoL
data at baseline (EQ-5D-5L index score) as an explanatory
variable for survival. Sensitivity analyses addressed differ-
ences between countries. Treatment type was not included
in the analyses as this was highly correlated with country, the
DOACs were not reimbursed in Italy and Spain at the time of
the data collection.
Missing data. There was missing information due to lost follow-
up (death or incomplete data), at each follow-up. No imputa-
tion was conducted for any missing value in the main analysis.
However, the difference in baseline characteristics between
patients who completed the follow-ups and those who did not
were tested, using w2, rank-sum test, or t test where appropriate.
Furthermore, a sensitivity analysis, using the multiple imputa-
tion technique to generate values for missing data, was con-
ducted to evaluate the potential impact of missing data.
Baseline characteristics and available index scores at different
time points were used for imputing missing data.
Results
Patients Characteristics
Among 2056 patients with DVT at baseline (Table 1), mean age
was 59.8 and 52.9% were male; 30.3% of patients were from
DACH, followed by Italy 28.0%, the United Kingdom 18.2%,
Spain 12.0%, and France 11.6%. One-quarter of patients with
DVT had previous VTE events, 71.3% were proximal (28.7%
were distal DVT), and 27.5% were provoked DVT. Deep vein
thrombosis can be provoked (defined by having prolong immo-
bilization, >5 days in bed, or history of major surgery or
trauma)—or unprovoked, but accompanied with comorbidities.
Of the provoked patients, 5.1% had a known thrombophilia
condition at baseline, while this percentage was 8.5% in
patients without provoked DVT. The most common comorbid-
ity among the patients with DVT was hypertension (39.7%).
One-third (30.3%) of patients had a smoking history. Com-
monly reported DVT symptoms included pain (82.8%) and
swelling (73.4%). In 8.5% of patients, active cancer was diag-
nosed. Most patients received heparin at baseline (64.9%), fol-
lowed by VKAs (42.7%). Only 26.8% of patients used DOACs
(mostly in France and DACH). Detailed baseline characteristics
per country are reported elsewhere.7 Patients with active cancer
were significantly older and had a higher proportion of liver
disease and history of major surgery or trauma. Patients with
active cancer had fewer previous VTE events and reported less
alcohol use, cardiovascular disease, prolonged immobilization,
and varicose veins. The percent of patients with active cancer
differed substantially between countries. In DACH, Spain, and
the United Kingdom, less than 5% of the included patients had
active cancer, in France 12.2% and in Italy 15.8% of the
patients who were included had active cancer. At baseline,
patients with active cancer were most often treated with heparin
and significantly less (than those without active cancer) with
VKAs or DOACs. Direct oral anticoagulants were infrequently
used in Italy and Spain at the time of the data collection.7
Health-Related Quality of Life
At baseline, 1921 patients completed the HrQoL questionnaire,
1366 at 1 month, 1163 at 3 months, 1013 at 6 months, and 847
patients completed the HrQoL questionnaire at 12 months.
Figure 1 presents the distribution of each dimension of EQ-
5D-5L and death at baseline and each follow-up for patients
with active cancer and those without. Among 5 assessment
time points, baseline had the highest proportion of patients
reporting problems for each dimension. Furthermore, among
the 5 dimensions, self-care was the dimension where patients
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reported fewest problems, while pain/discomfort had the high-
est proportion of reported problems. In patients without active
cancer, trends showing less problems or indicating less severity
of problems over time were seen across dimensions. Findings
were similar for patients with active cancer, although less obvi-
ous due to the high mortality rate. The mean EQ-5D-5L index
score moved from 0.717 at baseline to 0.866 at month 12 in
patients without active cancer, whereas in patients with active
cancer, the mean index score changed from 0.700 to 0.788 over
this time, showing a small increase in EQ-5D-5L index score in
both groups (Figure 2). The index score at month 12 of patients
without active cancer is similar to that of the average UK
population, which based on a recent UK valuation study can
be estimated at 0.852.10 When death was scored as 0, a
substantial drop in index score over time was observed in
patients with active cancer. This is explained by a higher pro-
portion of death occurring in the cancer group.
The Tobit repeated-measures regression on EQ-5D-5L
index scores for patients without active cancer, excluding the
presence of bleeds and recurrent VTE events, showed signif-
icant effects for a selection of factors (Table 2). Male gender
and thrombophilia were associated with a higher EQ-5D-5L
index score, suggesting a protective effect. Adding a recurrent
VTE event and bleed as predictors in the model showed these
events have no significant impact on EQ-5D-5L index score.
Thus, although the effect of the events on index score is neg-
ative, having additional events on top of the index event does
not appear to decrease HrQoL in a statistically significant
Table 1. Patients’ Characteristics at Baseline.
Active Cancer Active Cancer
Baseline, %
Total
N ¼ 2056
With,
N ¼ 174
Without,
N ¼ 1882 Baseline, %
Total
N ¼ 2056
With,
N ¼ 174
Without,
N ¼ 1882
Age, years, mean (SD) 59.8 (16.8) 59.1 (17.0) 67.9 (11.9)a
Male 52.9 52.7 55.8 Comorbidities
BMI, mean (SD) 27.8 (5.3) 27.9 (5.3) 26.4 (5.1) Active cancer 84.6 100.0 0.0
Highest graduation Hypertension 39.7 39.5 41.4
Primary school 26.7 25.6 38.5 Congestive heart failure 2.8 2.8 3.5
Secondary school 47.7 48.0 44.3 Vascular disease 5.5 5.3 7.5
Above 20.9 21.4 15.5 Dyslipidemia 17.5 17.5 17.8
Marital status Diabetes 9.7 9.5 12.6
Single 13.8 15.6 6.3 Chronic venous insufficiency 16.6 17.1 10.9
Married/living as married 65.7 64.8 75.3 Renal disease 6 5.8 8.7
Separated/divorced 5.7 6.0 3.5 Liver disease 2.6 1.9 9.8a
Widowed 10.8 10.5 13.2 Chronic respiratory disease 7.6 7.7 6.3
Other 1.1 1.1 1.2 Arthritis 8.8 9.1 5.2
Country Bone fracture/soft-tissue trauma 12.4 13.0 6.3a
France 11.6 11.1 16.7a Lower extremity paralysis 1.2 1.2 1.2
DACH 30.3 31.8 14.4 Thrombophilia 7.5 7.9 4.0
Italy 28.0 25.7 52.3a Cardiovascular disease 12.9 12.6 15.5
Spain 12.0 12.4 6.9
The United Kingdom 18.2 19.0 9.8 Risk factors (within past 3 months or ongoing)
Previous clinical event (within 3 years prior to enrollment) Alcohol use 18.4 19.4 7.5a
Myocardial infarction 3.1 2.9 4.6 Smoking history 30.3 30.5 27.8
Coronary artery disease 3.8 3.6 5.8 Prolong immobilization 15.9 16.2 12.1a
Percutaneous coronary
intervention
1.8 1.7 2.9 >5 days in bed 9.9 9.6 13.9
Atrial fibrillation 2.6 2.5 4.1 Varicose veins 22.1 22.8 14.9a
Transient ischemic attack 2 2.0 2.3 Major surgery or trauma 14.4 14.1 17.2a
Stroke 2.2 2.2 2.3 DVT symptoms present
Bleeding event 3.6 3.3 6.9 Pain 82.8 83.9 71.3
Clinical factors Discoloration 16.2 16.2 16.1
Previous VTE event 25.7 26.8 13.8a Calf tenderness 29.4 29.6 27.0
Proximal 71.3 71.2 71.8 Swelling 73.4 73.2 75.3
Provoked 27.5 27.4 27.8 Collateral superficial veins 7.3 7.2 8.1
Baseline treatment Other 5.8 5.5 9.2
Use of heparin 64.9 83.9 63.1a
Use of VKA 42.7 17.8 45.0a
Use of DOACs 26.8 5.7 28.7a
Abbreviations: DACH, Austria, Switzerland, and Germany; DOAC, direct oral anticoagulants; DVT, deep vein thrombosis; SD, standard deviation; VKA, vitamin K
antagonists; VTE: venous thromboembolism.
aDifference between the groups with/without active cancer reached statically significant level at P < .05.
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magnitude. When repeating the above regression analyses and
adding country as a predictor (the United Kingdom as the
reference country), patients from France, DACH, or Italy
without active cancer were associated with a significantly higher
EQ-5D-5L index score. In other words, after correction for base-
line and clinical characteristics (ie, patient case mix), significant
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Figure 1. A, Distribution of EQ-5D-5L domains and death at baseline and follow-up for patients without active cancer. B, Distribution of
EQ-5D-5L domains and death at baseline and follow-up for patients with active cancer.
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differences between countries remain. For patients with active
cancer, age, prolonged immobilization and bone fracture/soft-
tissue trauma were associated with a lower EQ-5D-5L index
score, while male gender and previous VTE events were asso-
ciated with a higher EQ-5D-5L index score. Country effects
were not present for patients with active cancer.
The results of sensitivity analyses, addressing potential
selection bias, were mostly aligned with the main results. As
shown in Appendix Figure 1, after the imputation, the trend of
improvement over time was less obvious compared to that in
the main analysis (without imputation, Figure 2B). The same
set of significant covariates was observed in the Tobit regres-
sion using the imputed data.
Missing Data
Patients who did not complete EQ-5D-5L at 12 months follow-
up were younger, mostly British, and with less dyslipidemia,
chronic venous insufficiency, and thrombophilia, but more
smoking history.
Mortality
The mortality rate at 12 months for patients with DVT was
7.3% (128/1766 patients with mortality information). The mor-
tality rate differed among countries, 6.7% (14/210) in France,
2.9% (16/554) in DACH, 15.4% (75/487) in Italy, 6.1% (14/
228) in Spain, and 3.1% (9/287) in the United Kingdom
(P value .0001). Moreover, there was a clear distinction
between cancer subgroup, as 43.0% with active cancer and
3.8% without active cancer died within a year. In comparison,
the age- and gender-adjusted (reflecting DVT study popula-
tion) annual mortality rate of a UK general population was
estimated at 2.1%.
Table 3 presents the cause of death at each follow-up time
point for all patients with DVT and by cancer subgroup.
Among all observed deaths, only 3.1% were VTE related. This
proportion is almost similar in the cancer subgroups. A differ-
ence between the 2 groups was observed in cardiovascular
death, which was more common in patients without active
cancer (11.5% vs 3.0%).
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Figure 2. A, EQ-5D-5L index score at baseline and follow-up by country. B, EQ-5D-5L index score at baseline and follow-up by patients with
and without active cancer.
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Table 4 presents the results from 2 models analyzing mor-
tality as a function of patient characteristics with a breakdown
in patients with active cancer and those without, including and
excluding HrQoL as an explanatory variable. In patients with-
out active cancer, increasing age, decreasing BMI, more than 5
days in bed, major surgery, varicose veins, previous atrial
fibrillation, liver disease, smoking history, and alcohol use
showed a significant association with all-cause mortality. Most
effects are positive, having an association with higher mortality
(odds ratio [OR] > 1). Body mass index, major surgery, var-
icose veins, and alcohol use show protective effects (lower
mortality, OR < 1). In patients with active cancer, BMI, var-
icose veins, and liver disease were significant predictors.
Health-related QoL index score showed a significant
association with mortality in both cancer groups without major
changes in the effects of the other variables. No country effects
were seen in any models when repeating the above regression
analyses with the addition of this as a predictor (the United
Kingdom as the reference country).
Discussion
This study aimed to contribute to current scientific knowl-
edge regarding the burden of DVT in Europe, based on real-
world data as collected in PREFER. The EQ-5D-5L index
score was 0.136 lower (0.716 at baseline) in patients with
DVT than that in the reference UK population (0.852). Fol-
lowing treatments, the HrQoL normalizes over 12 months,
Table 2. Tobit Regression on EQ-5D-5L Index Score.
Excluding Recurrent VTE /Bleeding
Event (n ¼ 1695, obs ¼ 5638)
Including Recurrent VTE /Bleeding
Event (n ¼ 1695, obs ¼ 5365)
Coefficient
Standard
Error P > z
95% Confidence
Interval Coefficient
Standard
Error P > z
95% Confidence
Interval
Patient without active cancer
Constant 0.982 0.036 0 0.911 to 1.052 0.987 0.036 0 0.916 to 1.058
Age 0.001 0.000 .009 0.002 to 0.000 0.001 0.000 .007 0.002 to 0.000
Male 0.082 0.011 0 0.061 to 0.103 0.080 0.011 0 0.059 to 0.102
BMI 0.003 0.001 .009 0.005 to 0.001 0.003 0.001 .009 0.005 to 0.001
Previous stroke 0.098 0.038 .011 0.173 to 0.022 0.099 0.039 .011 0.175 to 0.023
Previous bleed events 0.070 0.030 .019 0.129 to 0.011 0.071 0.030 .02 0.130 to 0.011
Prolonged immobilization 0.036 0.017 .031 0.068 to 0.003 0.034 0.017 .04 0.067 to 0.002
>5 days in bed 0.104 0.021 0 0.145 to 0.063 0.100 0.021 0 0.142 to 0.059
Lower extremity paralysis 0.227 0.052 0 0.330 to 0.124 0.229 0.053 0 0.332 to 0.125
Congestive heart failure 0.114 0.034 .001 0.181 to 0.048 0.109 0.035 .002 0.176 to 0.041
Chronic respiratory disease 0.055 0.021 .007 0.096 to 0.015 0.057 0.021 .006 0.098 to 0.016
Arthritis 0.084 0.019 0 0.121 to 0.047 0.083 0.019 0 0.120 to 0.046
Bone fracture/soft-tissue trauma 0.075 0.016 0 0.106 to 0.043 0.074 0.016 0 0.106 to 0.042
Smoking history 0.031 0.012 .009 0.054 to 0.008 0.033 0.012 .006 0.057 to 0.010
Thrombophilia 0.048 0.019 .014 0.010 to 0.086 0.047 0.020 .016 0.009 to 0.086
Proximal VTE event 0.048 0.012 0 0.072 to 0.024 0.048 0.012 0 0.072 to 0.024
Recurrent VTE event during
follow-up
Not included 0.008 0.032 .811 0.070 to 0.055
Bleeding event during follow-up Not included 0.013 0.027 .634 0.065 to 0.040
Excluding Recurrent VTE/Bleeding
Event (n ¼ 158; obs ¼ 459)
Including Recurrent VTE/Bleeding
Event (n ¼ 158; obs ¼ 415)
Coefficient
Standard
Error P > z
95% Confidence
Interval Coefficient
Standard
Error P > z
95% Confidence
Interval
Patient with active cancer
Constant 1.184 0.114 0 0.961 to 1.406 1.162 0.115 0 0.936 to 1.388
Age 0.007 0.002 0 0.010 to 0.004 0.007 0.002 0 0.010 to 0.003
Male 0.083 0.038 .029 0.009 to 0.158 0.075 0.038 .052 0.001 to 0.150
Prolonged immobilization 0.193 0.060 .001 0.310 to 0.076 0.185 0.061 .002 0.304 to 0.065
Bone fracture/soft-tissue trauma 0.184 0.073 .012 0.328 to 0.041 0.184 0.073 .012 0.328 to 0.040
Previous VTE event 0.129 0.055 .019 0.022 to 0.237 0.120 0.055 .029 0.012 to 0.228
Recurrent VTE event during
follow-up
Not included 0.077 0.062 .217 0.198 to 0.045
Bleeding event during follow-up Not included 0.076 0.082 .354 0.236 to 0.084
Abbreviations: BMI, body mass index; Obs.: number of observations of index scores (per patient could contribute multiple, up to 5, observations); VTE, venous
thromboembolism.
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particularly noticeably in patients with nonactive cancer
(0.866). The mortality results show substantial differences
in cancer subgroups, 43.0% for patients with active cancer
and 3.8% for those without at 12 months. Both groups had
excess mortalities, higher than that of the age- and gender-
adjusted UK mortality.
Utility
Overall, patients had the worst index scores at baseline (after
the index event) and the scores gradually improved over time.
Furthermore, larger differences are seen when evaluating
patients with and without active cancer. The observed improve-
ment of the index score was based on the alive patient popu-
lation who participated in the follow-up. With the inclusion of
patients who died (with a score of 0), the average index score
decreased. One must note that patients who were lost to follow-
up usually tend to be less healthy with lower EQ-5D-5L index
scores and so results should be interpreted with caution. As
demonstrated in Appendix Figure 1, after including the
imputed missing values, the improvement over time was rela-
tive limited, particularly for survivors with cancer.
The analyses of HrQoL and patient characteristics included
some unexpected results. For patients without active cancer,
there is a suggestion that thrombophilia significantly improves
HrQoL, which may be due to unobserved interaction, con-
founding, or possibly the patients’ interest in general health
and preventive therapies. For patients with active cancer, pre-
vious VTE event was significantly associated with a higher
EQ-5D-5L index score. Tobit repeated-measures regression
model results will be less robust because of the small sample
size of the active cancer group, incurring wider confidence
intervals for the predictors included in the models. When
including country as a predictor for EQ-5D-5L index score,
France, DACH, and Italy (vs the United Kingdom) were found
to be significant predictors of improved EQ-5D-5L index score.
Thus, even after correcting for case mix, differences between
countries are found. This implies that there may be other fac-
tors contributing to this difference in EQ-5D-5L index score
that were not included in the current analysis.
To the authors’ best knowledge, the current study is the first
reporting EQ-5D-5L data in patients with DVT outside clinical
trials. A few studies examined HrQoL of patients with DVT
using EQ-5D 3 level.12-14 Utne et al showed that EQ-5D-3L
index score (0.72) after a mean follow-up time of 5 years in 254
patients with previous DVT was lower than age- and sex-
matched “buddy” controls. The index score was also signifi-
cantly lower than age- and sex-adjusted population norms.12
Marvig et al13 evaluated newly diagnosed patients with VTE
and found similarly to our study an improvement of the index
score over time after evaluating complete cases only at baseline
and 3 months follow-up. The authors also reported between-
country differences in HrQoL of patients with VTE. Their
study suggested various factors that might explain the country
variation, such as different response style, reference levels,
external factors, and cultural differences.13 However, compar-
isons of our study with those in the literature should be
Table 3. Mortality Over Time.
BL F1 F3 F6 F12
All
Total 2056 2034 1899 1833 1766
Death, n (%) 8 (0.4) 29 (1.4) 70 (3.7) 100 (5.5) 128 (7.3)
Reason for death
Missing/unknown – 7 (24.1) 14 (20.0) 20 (20.0) 23 (18.0)
VTE-related death 1 (12.5) 1 (3.4) 2 (2.9) 3 (3.0) 4 (3.1)
Cardiovascular death – 2 (6.9) 4 (5.7) 7 (7.0) 9 (7.0)
Other 7 (87.5) 19 (65.5) 50 (71.4) 70 (70.0) 92 (71.9)
Patients without active cancer
Total 1882 1862 1736 1673 1610
Death, n (%) 5 (0.3)% 15 (0.8) 29 (1.7) 40 (2.4) 61 (3.8)
Reason for death
Missing/unknown – 3 (20.0) 6 (20.7) 7 (17.5) 10 (16.4)
VTE-related death 1 (20.0)% 1 (6.7) 2 (6.9) 2 (5.0) 2 (3.3)
Cardiovascular death – 2 (13.3) 3 (10.3) 5 (12.5) 7 (11.5)
Other 4 (80.0)% 9 (60.0) 18 (62.1) 26 (65.0) 42 (68.9)
Patients with active cancer
Total 174 172 163 160 156
Death, n (%) 3 (1.7) 14 (8.1) 41 (25.2) 60 (37.5) 67 (43.0)
Reason for death
Missing/unknown – 4 (28.6) 8 (19.5) 14 (23.3) 13 (19.4)
VTE-related death – – – 1 (1.7) 2 (3.0)
Cardiovascular death – – 1 (2.4) 2 (3.3) 2 (3.0)
Other 3 (100.0) 10 (71.4) 32 (78.0) 44 (73.3) 50 (74.6)
Abbreviations: BL, baseline; F1, 1 month follow-up; F3, 3 months follow-up; F6, 6 months follow-up; F12, 12 months follow-up.
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undertaken with caution due to differences in the populations
and the measurement tools used. Utne et al focused on long-
term effects of DVT and Marvig et al evaluated newly diag-
nosed patients with VTE up to 3 months. Furthermore, our
study used EQ-5D-5L, which is not comparable with the 3L
version.
Mortality
A wide range of 1-year mortality rates was observed across
countries (2.9% in DACH to 15.4% in Italy). Several factors
may have contributed to this variation. First, in Italy and
Spain, only inpatients were recruited, whereas in France,
DACH, and the United Kingdom, both inpatients and out-
patients were included. We found considerably more patients
with active cancer in Italy and France (15.8% and 12.2%,
respectively). In other words, countries may have included a
dissimilar “mix” of patients. Second, there is variation in
disease management across countries. For instance, not all
DOACs were available in Spain and Italy at the time of data
collection. The use of DOACs in the United Kingdom was
also low (19.25%) in comparison to France and DACH
(42.0% and 54.4%, respectively). However, when controlling
for case mix (age, gender, BMI, previous clinical events,
clinical factors, comorbidities, risk factors, and DVT symp-
toms at baseline, as well as EQ-5D-5L index score), the
regression results showed that country variation was not a
significant predictor for survival in patients with or without
active cancer. This suggests that the higher mortality in Italy
versus the United Kingdom can mostly be explained by dif-
ferences in patient characteristics.
The study also showed a substantial difference in mortality
between patients with and without active cancer. For patients
without active cancer (91.5% of the total DVT sample), the
mortality rate at 12 months was 4.7%. This still implies an
excess mortality of 2.6% compared to the age- and gender-
adjusted general population. Regression results of this sub-
group showed that high BMI, major surgery, varicose veins,
and alcohol use had a protective effect on the 12-month mor-
tality rate. One could argue that these predictors are present in a
relatively healthy group and that short-term mortality in these
patients is lower compared to more severe comorbidities and
risk factors. As for the patients with active cancer (8.5% of the
DVT sample), 43% died within a year. As in the PREFER
registry, patients with VTE cancer with a poor prognosis were
less likely to be included, the current estimate can be consid-
ered as conservative. A recent trial analysis in patients with
cancer with DVT (with or without PE) reported a 23.9%
Table 4. Logistic Regression on 12-Month Mortality Rate.
Baseline Characteristics, n ¼ 1502
Baseline Characteristics and
EQ-5D-5L Index Score, n ¼ 1469
Odds
Ratio
Standard
Error P Value
95% Confidence
Interval
Odds
Ratio
Standard
Error P Value
95% Confidence
Interval
Patients without active cancer
Constant 0.012 0.015 0 0.001-0.134 0.059 0.073 .022 0.005-0.664
Age 1.063 0.012 0 1.041-1.086 1.066 0.012 0 1.043-1.089
Body mass index 0.894 0.032 .002 0.833-0.959 0.878 0.031 0 0.820-0.940
>5 days in bed 2.426 0.871 .014 1.200-4.905
Major surgery 0.261 0.171 .04 0.072-0.944 0.281 0.180 .047 0.080-0.985
Varicose veins 0.333 0.137 .007 0.149-0.745 0.351 0.145 .011 0.156-0.789
Previous atrial fibrillation 4.462 2.179 .002 1.713-11.622 3.820 1.907 .007 1.436-10.163
Liver disease 4.644 2.856 .013 1.392-15.499 4.186 2.540 .018 1.274-13.751
Smoking history 2.279 0.687 .006 1.262-4.113 2.042 0.619 .019 1.127-3.700
Alcohol use 0.348 0.177 .038 0.128-0.945
EQ-5D-5L index score Not included 0.161 0.080 0 0.061-0.427
Baseline Characteristics, n ¼ 152
Baseline Characteristics and
EQ-5D-5L Index Score, n ¼ 149
Odds
Ratio
Standard
Error P Value
95% Confidence
Interval
Odds
Ratio
Standard
Error P Value
95% Confidence
Interval
Patients with active cancer
Constant 1.187 1.849 .912 0.056-25.147 68.221 90.589 .001 5.054-920.890
Age 1.037 0.017 .027 1.004-1.071
Body mass index 0.896 0.041 .015 0.819-0.979 0.911 0.041 .041 0.834-0.996
Varicose veins 0.140 0.095 .004 0.037-0.531 0.111 0.082 .003 0.026-0.472
Liver disease 6.227 4.245 .007 1.637-23.689 5.737 4.089 .014 1.419-23.190
EQ-5D-5L index score Not included 0.059 0.048 0 0.012-0.289
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mortality rate at 6 months in patients with standard therapy.15
However, most mortality rates reported in recent randomized
controlled trials for DOACs tend to be lower, which is likely
related to the selection of relatively healthy patients.
Our study reported a mortality rate of 7.3% at 12 months,
which is lower than the numbers reported in other population
cohort studies with long-term follow-up. A nationwide
population-based cohort study in Denmark following first-
time VTE diagnosed patients over the period of 30 years
reported a 31- to 364-day mortality rate of 13% for patients
with DVT.16 The study also reported that mortality after DVT
remained fairly constant over the past 3 decades. A Norwegian
population-based study of 740 patients with a first-time VTE
reported 1-year mortality rate of 21%.17 Martinez et al18
reported a mortality rate of 21.6% after 1 year for patients with
VTE, using the UK Clinical Practice Research Datalink with
Hospital Episodes Statistics. In addition, Cohen et al19 reported
64.5% mortality after 1 year for patients with DVT with active
cancer based on the same UK data set. The fact that the current
study includes both first-time diagnosed and recurrent patients
with DVT may contribute to the observed differences. The
2-week recruitment window might also result in recruiting
less severe patients.
Strengths and Limitations
The PREFER in VTE registry provides a rich data source of
epidemiology, management, and outcomes of VTE based on a
large sample with frequent timings of measurements in a real-
world setting. It is one of largest prospective disease registries
in VTE. The PREFER in VTE collected data from 7 European
countries, providing much-needed data in the light of current
scarcity of data for the region. Furthermore, the design of PRE-
FER—including both proximal and distal DVT—allowed all
types of patients with DVT to be recruited, providing a source
of heterogeneous data in a real-world setting. Similarly, the
PREFER registry was conducted at time when DOACs avail-
ability varied among countries, offering a unique opportunity
of understanding the potential impact of DOACs.
The main limitation of the study is missing data, which is
not a unique problem to this registry. There are many possible
approaches to impute missing values; however, in this study,
the multiple imputation method was employed and resulted in a
similar finding as that of the main analysis, particularly the
factors determining the HrQoL. It is unclear to what extent the
approach to include subsequent patients who fulfilled the inclu-
sion criteria may have given a higher likelihood to include
relatively mild, returning patients thus underestimating the
impact of DVT on mortality and HrQoL. The causes of death
were not adjudicated by a centralized committee and this is also
a limitation.
Conclusion
The HrQoL in patients with DVT at baseline are below age-
adjusted UK estimates. The mortality rates are higher than the
average mortality rates in the general UK population. Even
after distinguishing between patients with DVT with and with-
out active cancer, an excess in the burden of illness, as mea-
sured by HrQoL and mortality in patients with DVT compared
to the general population, was found. Following treatments, the
HrQoL normalizes over 12 months, particularly noticeably in
patients with nonactive cancer.
Appendix A
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Figure A1. Imputed 5-level EQ-5D instrument index score at baseline and follow-up by patients without active cancer and with active cancer.
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